Technology | Genetic Testing | October 08, 2015

Invitae Expands Cardiology Genetic Testing Offerings

Testing menu now covers more than 190 genes for a variety of hereditary cardiovascular disorders

Invitae Corp., cardiovascular test panels, genetic testing, expands offerings

October 8, 2015 — Invitae Corp., a genetic information company, announced the expansion of its cardiology offering, including more than 30 cardiovascular test panels for arrhythmias, cardiomyopathies, aortopathies, familial hypercholesterolemia, pulmonary hypertension and congenital heart disease. 

Genetic cardiac conditions may be difficult to diagnose. Often, the first evidence of a hereditary cardiac condition is the sudden death of an otherwise healthy person, sometimes in infancy or childhood. Invitae’s expanded cardiovascular test menu allows the company to provide first-line genetic testing for inherited arrhythmia and cardiomyopathy conditions, including sudden cardiac arrest or death, as well as inherited aortic diseases and familial hypercholesterolemia, one of the most common inherited cardiovascular conditions. This comprehensive cardiology offering includes a rigorous, evidence-based variant classification process developed by a team of board-certified genetic counselors, Ph.D. scientists, and physicians with special expertise in the genetic testing for hereditary cardiovascular disorders. 

“Heart disease is the number one cause of death in our country, and there are a number of red flags that could indicate when there’s genetic heart disease in the family,” said Amy Sturm, MS, LCGC, associate professor and genetic counseling expert at the Ohio State University. 

Sturm encourages everyone to pay attention to the following types of events in their family health history: 

  • A relative diagnosed with heart disease at an early age;
  • Multiple family members who have had a heart attack, an abnormal heart rhythm, heart failure or a heart transplant; and
  • A relative who died suddenly or had an unexplained death. 

With this offering, Invitae’s cardiology menu will expand to more than 190 genes. Clinicians can easily choose the right test for their patient, with no penalty for starting with large or small panels, because of Invitae’s policies of charging a flat price per indication — regardless of the number of genes ordered — as well as allowing physicians to re-requisition additional genes for the same condition within 90 days for no additional charge. 

According to patient advocacy organization the Sudden Arrhythmia Death Syndromes (SADS) Foundation, making testing more accessible is key. “We believe that with genetic information families can better understand their genetic risks and when necessary, take preventive action,” the organization stated in their recent newsletter. “Lowering costs of testing and making tests easier to get will help families everywhere. We believe that by working to make these genetic tests more available and affordable we are giving families information that will help save lives.” 

Invitae offers a transparent pricing structure independent of the number of genes required to provide an accurate diagnosis for any specific clinical indication. For payers and institutions who are in contract with Invitae, the price per indication can be as low as $950, depending on the payer’s requirements. For third-party payers with whom Invitae is out of network and for non-contracted institutions, the price per indication remains $1,500. In addition, for patients without third-party insurance coverage or who do not meet insurance criteria for coverage, Invitae offers its full test menu for $475 per indication for patients whose clinician has ordered the testing online and who register online and pay in advance for the testing. 

For more information: www.ir.invitae.com

Related Content

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
News | Blood Testing | March 22, 2016
March 22, 2016 — Critical Diagnostics announced that it entered into a license agreement for the exclusive worldwide
Overlay Init